Randomized trial · people
Pramlintide/insulin ADO09 cut meal glucose rise 69% in high-dose group
Checked against the paper Randomized trialPublished by PepVault
The takeaway
Putting pramlintide and insulin in one mealtime shot improved short-term glucose control and weight compared with aspart, with slightly more low blood sugar events and gut side effects.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2023
- Journal
- Diabetes Obes Metab
What they tested
The team tested whether ADO09, a single shot that combines pramlintide with insulin A21G, controls blood sugar better than insulin aspart in adults with type 1 diabetes.
How the study was done
A double-blind, randomized crossover trial: each adult with type 1 diabetes used ADO09 and insulin aspart at mealtimes, for 24 days each. People were split by their daily mealtime insulin needs into a low-dose group of 28 (40 U or less) and a high-dose group of 16 (40 to 75 U).

Model. Individual results vary.
What they found
The main measure was the rise in blood sugar over the 4 hours after a test meal. With ADO09 that rise was 69% lower in the high-dose group, and 39% lower in the low-dose group, though the low-dose result was not statistically significant. On continuous glucose monitors in daily life, average glucose was lower with ADO09 in both groups (by 8.2 ± 7.9 mg/dl in the low-dose group), and time in range (70-180 mg/dl) rose by 4% in each group. Body weight fell by 0.8 kg in the low-dose group and 1.6 kg in the high-dose group, while low blood sugar events were a little more common with ADO09 (142 vs. 115 and 96 vs. 79), and gut side effects were more frequent but mostly passed.
What it doesn’t show
Each treatment period lasted only 24 days and the groups were small, so this does not show long-term effects. It tested pramlintide combined with insulin A21G in one shot, not pramlintide on its own.
The paper
Andersen et al. A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes Obes Metab. 2023.
The compound
More studies on Pramlintide
- Pramlintide: HbA1c down 0.43% vs placebo at 26 weeks with insulinMeta-analysis · people · 2003
- Pramlintide-insulin loop: time in range held without carb countingRandomized trial · people · 2025
- Pramlintide-insulin mix: 2.1 kg more weight loss than lisproRandomized trial · people · 2024
- Pramlintide: weight loss maintained over 12 months in obesityRandomized trial · people · 2008
- Pramlintide: 3.7% placebo-corrected weight loss at 16 weeksRandomized trial · people · 2007
- Pramlintide lowered post-meal glucagon and glucose in type 2 diabetesRandomized trial · people · 2002
- Every study on Pramlintide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.